2023
Hybridan LLP – RNA oligonucleotide program shows in vitro anti-cancer efficacy
22 June 2023
Hybridan LLP – Midkine antibody in-vivo efficacy results and pursuit of an orphan drug indication (osteosarcoma)
19 June 2023
Hybridan LLP – Successful completion of in vitro studies of anti-cancer Midkine mRNA therapeutic
14 June 2023
Hybridan LLP – Licencing of Midkine IP to Randox
20 February 2023
2022
Hybridan LLP – Completion of Oncogeni Acquisition
16 September 2022
Hybridan LLP - Initiation of Coverage
12 September 2022
Optiva Securities - Research Report
17 May 2022
Pitt Street - Evaluation Report
10 January 2022